Important note

This AI stock analysis for Bristol-Myers Squibb is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Bristol-Myers Squibb - AI Stock Analysis

Analysis generated November 29, 2024

Bristol Myers Squibb (BMY) is a globally recognized biopharmaceutical company. It focuses on discovering, developing, and delivering innovative medicines that help patients overcome serious diseases. The company is known for its robust pipeline of potential products and a strong portfolio of existing therapies catering to oncology, cardiovascular, immunoscience, and fibrotic diseases.

The company has continuously strengthened its position in the biopharmaceutical industry through strategic acquisitions, robust research and development (R&D), and a diversified product mix. Bristol Myers Squibb has made significant progress, especially in the oncology segment, with the introduction of breakthrough therapies.

Fundamental Analysis

The revenue for the last quarter was $11.9 billion. This represents a 2.53% decrease compared to the quarter before it, indicating a short-term concern. However, the year-over-year growth presents a more positive outlook with an 8.44% increase compared to the same quarter last year, suggesting solid performance over a longer period.

Net income for the last quarter was $1.21 billion, which is a significant decrease of 27.92% from the quarter before, and even more concerning, it represents a 37.19% decrease compared to the same quarter last year. This decline could raise red flags about the company's profitability and cost management.

EBITDA for the last quarter came in at $129 million. While this marks a strong increase of 70.55% compared to the previous quarter, it's down 102.74% from the same quarter last year. Even though there's evident short-term growth, the long-term decrease requires close monitoring.

The current P/E ratio stands at 12.66, which is within a normal range compared to the company's historical valuations and industry standards. This suggests that the stock isn't overvalued or undervalued based on current earnings.

Technical Analysis

Today’s stock price is $59.13, marking a 12.63% increase over the past month and a 25.78% increase from a year ago. These numbers indicate a strong bullish trend in both the short and long term.

The current SMA10 is $58.79, showing a slight increase from the previous SMA10 of $58.70, which supports the upward trend in price movement. This indicates potential further upward momentum.

However, the RSI (Relative Strength Index) stands at 71, which signals that the stock is potentially overbought and there could be a bearish trend on the horizon. Investors should be cautious of a possible price correction.

Alternative Data Analysis

Analyzing alternative data, Bristol Myers Squibb has 916 open positions, and this number has been stable, indicating that the company is in a stable hiring phase. Employee sentiment is neutral, suggesting that there are no extreme positive or negative sentiments within the workforce.

The company’s customer acquisition seems to be weakening, with an estimated 910,000 visitors to their webpage, down by 16% over the last few months. This decline could be an indication of reduced customer interest or engagement.

Customer engagement on social media presents a mixed view. The company's Instagram page has 21,000 followers with no significant change, and its Twitter account has 160,000 followers, although there's been a 1% decline in followers recently, highlighting a slight downturn in social media engagement.

Bristol Myers Squibb’s AI score as shown by AltIndex is 39, which is interpreted as a sell signal. This AI score takes into account a comprehensive analysis of the company's fundamentals, technical indicators, and alternative data.

Conclusion and Recommendation

In conclusion, Bristol Myers Squibb presents both positive and negative signals. The company has shown promising year-over-year revenue growth and a strong short-term bullish trend in stock price. However, significant decreases in net income and EBITDA compared to the previous year, coupled with declining customer engagement numbers, warrant caution.

Given the mixed signals, particularly the concerning profitability metrics and the AI score of 39 indicating a sell signal, it is recommended to carefully monitor Bristol Myers Squibb’s stock. Investors should consider holding or potentially selling their positions until there are clear signs of sustainable financial improvement and stabilized customer metrics.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.